GP350 CAR-T for Epstein-Barr virus related lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new treatment called GP350 CAR-T for patients with lymphoma (a type of blood cancer) that has come back or not responded to standard therapy, especially when linked to Epstein-Barr virus (EBV) infection. The therapy uses your own immune cells, modified to target and kill cancer cells carrying the GP350 protein from EBV.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lymphoma (blood cancer) that has come back or not responded to standard treatment.
- Your cancer is linked to Epstein-Barr virus (EBV) infection, confirmed by a blood test, tumor test, or antibody test.
- You are between 18 and 70 years old.
- You are generally well enough to be up and about at least half the day (ECOG score 0-2).
- Your blood counts and organ function (kidney, liver, heart, lungs) are within acceptable limits.
- You are not pregnant, and you agree to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using your own immune cells (T cells) that are modified to find and attack cells infected with the Epstein-Barr virus (EBV). It is for people with certain blood cancers or chronic active EBV infection that has not improved with standard treatments.
This trial tests an investigational mRNA vaccine (WGc-043) that aims to help your immune system fight EBV-positive lymphoma cells. If you have tried standard treatments and your lymphoma is still active, this vaccine might offer a new option.
This study tests a combination of four drugs (an immunotherapy called a PD-1 inhibitor, an antiviral drug called tenofovir, and two other targeted therapies) for people whose EBV-related lymphoma has come back or not improved after treatment. The goal is to see if this combination can control the disease and help patients live longer.
This early-phase study tests a lab-made immune cell treatment (cytotoxic T-lymphocytes) for certain lymphomas and related diseases that test positive for the Epstein-Barr virus (EBV). It may help your immune system attack EBV-infected cancer cells, especially after the cancer has come back or when transplant isn’t suitable.
This trial tests a new cell therapy (TCR-T cells) for people with EBV-positive lymphoma that has not responded to standard treatments or has come back. The therapy uses your own immune cells that have been specially trained to find and attack cancer cells carrying the EBV virus.
This trial tests an immune therapy made from EBV-targeted T-cells to treat EBV infections that do not improve with standard anti-viral medicines. It may help by strengthening the body’s ability to fight EBV after certain transplants or immune problems.
Hear when a new EBV Associated Lymphoid Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.